¹⁸F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study.

ABSTRACT:

Objectives

The aim of this study was to [1] characterize distribution of Erdheim-Chester Disease (ECD) by ¹⁸F-FDG PET/CT and [2] determine the utility of metabolic (¹⁸F-FDG PET/CT) imaging versus anatomic imaging (CT or MRI) in evaluating ECD patients for clinical trial eligibility.

Methods

¹⁸F-FDG PET/CT and corresponding CT or MRI studies for ECD patients enrolled in a prospective registry study were reviewed. Sites of disease were classified as [1] detectable by ¹⁸F-FDG PET only, CT/MRI only, or both and as [2] measurable by modified PERCIST (mPERCIST) only, RECIST only, or both. Descriptive analysis was performed and paired t test for between-group comparisons.

Results

Fifty patients were included (mean age 51.5 years; r

SUBMITTER: Kirchner J 

PROVIDER: S-EPMC8041681 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature